Search hospitals > Pennsylvania > Philadelphia

Penn Presbyterian Medical Center

Claim this profile
Philadelphia, Pennsylvania 19104
Global Leader in Amyloidosis
Global Leader in Wounds and Injuries
Conducts research for Traumatic Brain Injury
Conducts research for Coronary Artery Disease
Conducts research for Non-Small Cell Lung Cancer
137 reported clinical trials
25 medical researchers
Photo of Penn Presbyterian Medical Center in PhiladelphiaPhoto of Penn Presbyterian Medical Center in PhiladelphiaPhoto of Penn Presbyterian Medical Center in Philadelphia

Summary

Penn Presbyterian Medical Center is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Amyloidosis, Wounds and Injuries, Traumatic Brain Injury, Coronary Artery Disease, Non-Small Cell Lung Cancer and other specialties. Penn Presbyterian Medical Center is involved with conducting 137 clinical trials across 216 conditions. There are 25 research doctors associated with this hospital, such as Sabine s Coppieters, MD, Wilson Szeto, MD, Howard Herrmann, MD, and Benjamin D'Souza.

Area of expertise

1Amyloidosis
Global Leader
Penn Presbyterian Medical Center has run 12 trials for Amyloidosis. Some of their research focus areas include:
TTR
Stage I
Stage II
2Wounds And Injuries
Global Leader
Penn Presbyterian Medical Center has run 11 trials for Wounds and Injuries. Some of their research focus areas include:
AIS A

Top PIs

Clinical Trials running at Penn Presbyterian Medical Center

Non-Small Cell Lung Cancer
Heart Failure
Lung Cancer
Amyloidosis
Traumatic Brain Injury
Prostate Cancer
Cardiac Arrest
Plantar Fasciitis
Cardiomyopathy
Cancer
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Liquid Biopsy NGS Prompt

for Lung Cancer

This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implementation is successful.
Recruiting1 award N/A2 criteria
Image of trial facility.

Genetic Testing

for Early-Stage Lung Cancer

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Penn Presbyterian Medical Center?
Penn Presbyterian Medical Center is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Amyloidosis, Wounds and Injuries, Traumatic Brain Injury, Coronary Artery Disease, Non-Small Cell Lung Cancer and other specialties. Penn Presbyterian Medical Center is involved with conducting 137 clinical trials across 216 conditions. There are 25 research doctors associated with this hospital, such as Sabine s Coppieters, MD, Wilson Szeto, MD, Howard Herrmann, MD, and Benjamin D'Souza.